<var id="thnxb"><strike id="thnxb"></strike></var><var id="thnxb"></var>
<cite id="thnxb"><video id="thnxb"><menuitem id="thnxb"></menuitem></video></cite>
<menuitem id="thnxb"><strike id="thnxb"><listing id="thnxb"></listing></strike></menuitem>
<var id="thnxb"></var>
<cite id="thnxb"><video id="thnxb"><menuitem id="thnxb"></menuitem></video></cite>
<cite id="thnxb"></cite>
<var id="thnxb"></var>
中文版 | English

Home

About Us

Company Profile

Home >Company Profile

Chongqing Daxin Pharmaceutical Co., Ltd. (herein referred as Chongqing Daxin) was established in 1941. It is a core member of PKU HealthCare Industry,which has been praised as the Key High-tech Enterprise of the National Torch Program, Nationwide Key Enterprise in Chemical and Pharmaceutical Industry, one of the National Top 100 Pharmaceutical Enterprises and the Exportation brand leader enterprise supported by Chongqing government. After over 70 year's development, it has become a biotech oriented and comprehensive pharmaceutical company which covers areas of APIs and finished dosages.

Chongqing Daxin Pharmaceutical Co., Ltd. is the largest manufacturing base of Lovastatin in the world with strong pharmaceutical manufacturing capability which owns advanced medical manufacturing equipments and two large-scale pharmaceutical manufacturing bases, including a new base complying with international GMP standards located in Shuitu, Liangjiang New District, Chongqing City. There are about hundred of APIs, finished dosages and intermediates, including cardio-vascular, antibiotics, immunosuppressant, plasma volume expander, and etc.

In 2009, PKU Healthcare Corp., Ltd (herein referred as PKU Healthcare) acquired Chongqing Daxin Pharmaceutical Co., Ltd. through directional add-issuance, completing the pharmaceutical industry structure with biomedical and chemical synthesis, realizing the power-and-power union and further improving the industry status. PKU HealthCare and Chongqing Daxin, both located in Chongqing area, have become the largest export manufacturing base in Chongqing.

Chongqing Daxin has got a perfect quality assurance system. All the products receive GMP certificate, and five of them have been approved by US FDA. Chongqing Daxin can provide customers high quality products consistent with the latest specifications of CP, USP, EP, etc.

Chongqing Daxin has got a Technology Research Center for Industrial Microbial Pharmaceutical Engineering, which is devoted to biological medicine R&D and product technology improvement. The center is equipped with laboratories for Microbial breeding and Fermentation technology, Separation Purification and Semi-synthetic drugs, and with Formulation development pilot workshop. In recent years, the center has successfully developed many new products, applied for 3235 invention patents and 5 licensed patents, taken part in 3 projects of the National Torch Program, and acquired two major national new drug projects.

Based on the supporting of Peking University and continuous innovation, Chongqing Daxin, in accordance with the whole strategy of PKU  HealthCare Induetry Group, will actively promote the green pharmaceutical manufacturing, deepen the domestic and foreign exchanges and cooperation, manufature knock-out products, and make unremitting efforts to become a leader of bio-pharmaceutical industry in west of China on R&D, manufacturing and exportation

Main products( FDA approved)

There are five APIs are first approved by US FDA in China

Amikacin: The first approved by US FDA in China in January 1993 with DMF no.13760, and successfully passed many US FDA re-inspections afterwards.
Tobramycin: The first approved by US FDA in China in November 1993 with DMF no.13774, and have got COS issued by EDQM with no. ROCEP 1997-103

Amikacin Sulfate: The first approved by US FDA in China in August 1995 with DMF no.13788, and successfully passed many US FDA re-inspections afterwards.
Lovastatin: The first approved by US FDA site inspection in China in July 2005 with ZERO-483, DMF no.17821.

Mycophenolic Acid: The first approved by US FDA in China in August 2009 with DMF no.20452.

Chongqing Daxin made many “ First” in china:
The first R&D and manufacturer of Polyglucose plasma substitute
The first R&D and manufacturer of new anti-cancer and liver 
protection drug : Polystictus Glycopeptide
The first R&D and manufacturer of Midecamycin
The first successful generic plasma expander hydroxyethyl starch 130/0.4 
Many products are the first one approved by US FDA in China including: Amikacin, Amikacin Sulfate,Lovastatin and Mycophenolic Acid

欧美成人H版整片,又爽又黄又无遮挡的视频APP,亚洲AVAV天堂AV在线网,欧美成人R级在线观看
<var id="thnxb"><strike id="thnxb"></strike></var><var id="thnxb"></var>
<cite id="thnxb"><video id="thnxb"><menuitem id="thnxb"></menuitem></video></cite>
<menuitem id="thnxb"><strike id="thnxb"><listing id="thnxb"></listing></strike></menuitem>
<var id="thnxb"></var>
<cite id="thnxb"><video id="thnxb"><menuitem id="thnxb"></menuitem></video></cite>
<cite id="thnxb"></cite>
<var id="thnxb"></var>